Checkpoint Therapeutics (CKPT) Projected to Post Earnings on Friday

Checkpoint Therapeutics (NASDAQ:CKPT) is expected to be posting its quarterly earnings results before the market opens on Friday, March 28th. Analysts expect Checkpoint Therapeutics to post earnings of ($0.22) per share for the quarter.

Checkpoint Therapeutics Price Performance

CKPT stock opened at $4.06 on Friday. The company has a fifty day moving average price of $3.22 and a two-hundred day moving average price of $3.17. Checkpoint Therapeutics has a one year low of $1.38 and a one year high of $4.50. The stock has a market cap of $198.26 million, a price-to-earnings ratio of -2.21 and a beta of 1.41.

Insiders Place Their Bets

In other news, CEO James F. Oliviero III sold 9,233 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $3.41, for a total value of $31,484.53. Following the sale, the chief executive officer now directly owns 3,785,350 shares in the company, valued at approximately $12,908,043.50. This trade represents a 0.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO William Garrett Gray sold 74,110 shares of the firm’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $3.67, for a total transaction of $271,983.70. Following the completion of the sale, the chief financial officer now owns 1,458,644 shares in the company, valued at approximately $5,353,223.48. The trade was a 4.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 93,674 shares of company stock worth $336,011 over the last ninety days. Corporate insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Lake Street Capital reaffirmed a “hold” rating and set a $4.10 price objective (down from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. HC Wainwright restated a “neutral” rating and issued a $4.10 price target on shares of Checkpoint Therapeutics in a research note on Tuesday, March 11th. Finally, D. Boral Capital restated a “buy” rating and issued a $4.80 price target (down from $9.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.